UBS Group
RXII

UBS Group’s GALENA BIOPHARMA INC COM RXII Stock Holding History

UBS Group’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12,800
Closed -$19K – 8835
2015
Q4 		$19K Hold
12,800
– – ﹤0.01% 6843
2015
Q3 		$20K Hold
12,800
– – ﹤0.01% 6721
2015
Q2 		$22K Hold
12,800
– – ﹤0.01% 6804
2015
Q1 		$18K Sell
12,800
-16,200
-56% -$22.8K ﹤0.01% 7121
2014
Q4 		$44K Buy
+29,000
New +$44K ﹤0.01% 6666

UBS Group's RXII Position: Q4 2016 in Review

UBS Group sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,300 shares.

UBS Group first reported a position in RXII in Q4 2014 and held it in 8 quarters. The position peaked at $88K in Q4 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • UBS Group reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 1,300 GALENA BIOPHARMA INC COM shares in Q4 2016.
  • UBS Group first reported a position in GALENA BIOPHARMA INC COM in Q4 2014 and held it in 8 quarters.
  • UBS Group's GALENA BIOPHARMA INC COM position peaked at $88K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.